-
1
-
-
84859030420
-
Global prevalence and major risk factors of diabetic retinopathy
-
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
-
(2012)
Diabetes Care
, vol.35
, Issue.3
, pp. 556-564
-
-
Yau, J.W.1
Rogers, S.L.2
Kawasaki, R.3
-
2
-
-
78049293726
-
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
-
Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
-
(2010)
Ophthalmology
, vol.117
, Issue.11
, pp. 2146-2151
-
-
Nguyen, Q.D.1
Shah, S.M.2
Khwaja, A.A.3
-
3
-
-
84856397889
-
Diabetic retinopathy and inflammation: Novel therapeutic targets
-
Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19(1):52-59.
-
(2012)
Middle East Afr J Ophthalmol
, vol.19
, Issue.1
, pp. 52-59
-
-
Rangasamy, S.1
McGuire, P.G.2
Das, A.3
-
4
-
-
0033551811
-
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors
-
Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-23467.
-
(1999)
J Biol Chem
, vol.274
, Issue.33
, pp. 23463-23467
-
-
Antonetti, D.A.1
Barber, A.J.2
Hollinger, L.A.3
Wolpert, E.B.4
Gardner, T.W.5
-
5
-
-
84934932422
-
Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy
-
Behl T, Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol Res. 2015;99:137-148.
-
(2015)
Pharmacol Res
, vol.99
, pp. 137-148
-
-
Behl, T.1
Kotwani, A.2
-
6
-
-
84908118639
-
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
-
Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
-
(2014)
Ophthalmology
, vol.121
, Issue.10
, pp. 1904-1914
-
-
Boyer, D.S.1
Yoon, Y.H.2
Belfort, R.3
-
7
-
-
84925423332
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
-
Diabetic Retinopathy Clinical Research N
-
Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
-
(2015)
N Engl J Med
, vol.372
, Issue.13
, pp. 1193-1203
-
-
Wells, J.A.1
Glassman, A.R.2
-
8
-
-
79953311138
-
The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
-
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
-
(2011)
Ophthalmology
, vol.118
, Issue.4
, pp. 615-625
-
-
Mitchell, P.1
Bandello, F.2
Schmidt-Erfurth, U.3
-
9
-
-
84863401792
-
Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE
-
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
-
(2012)
Ophthalmology
, vol.119
, Issue.4
, pp. 789-801
-
-
Nguyen, Q.D.1
Brown, D.M.2
Marcus, D.M.3
-
10
-
-
84899837995
-
Current status in diabetic macular edema treatments
-
Romero-Aroca P. Current status in diabetic macular edema treatments. World J Diabetes. 2013;4(5):165-169.
-
(2013)
World J Diabetes
, vol.4
, Issue.5
, pp. 165-169
-
-
Romero-Aroca, P.1
-
11
-
-
84908897529
-
Intravitreal aflibercept for diabetic macular edema
-
Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
-
(2014)
Ophthalmology
, vol.121
, Issue.11
, pp. 2247-2254
-
-
Korobelnik, J.F.1
Do, D.V.2
Schmidt-Erfurth, U.3
-
12
-
-
79251606719
-
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study
-
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
-
(2010)
Diabetes Care
, vol.33
, Issue.11
, pp. 2399-2405
-
-
Massin, P.1
Bandello, F.2
Garweg, J.G.3
-
13
-
-
12744266491
-
Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown
-
Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80(2):249-258.
-
(2005)
Exp Eye Res
, vol.80
, Issue.2
, pp. 249-258
-
-
Edelman, J.L.1
Lutz, D.2
Castro, M.R.3
-
14
-
-
50249149459
-
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
-
Diabetic Retinopathy Clinical Research Network 1449.e1-10
-
Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-1449, 1449.e1-10.
-
(2008)
Ophthalmology
, vol.115
, Issue.9
, pp. 1447-1449
-
-
-
15
-
-
42549132257
-
Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors
-
Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors. Retina. 2008;28(4):573-580.
-
(2008)
Retina
, vol.28
, Issue.4
, pp. 573-580
-
-
Vasconcelos-Santos, D.V.1
Nehemy, P.G.2
Schachat, A.P.3
Nehemy, M.B.4
-
16
-
-
84860197211
-
Diabetic macular edema
-
Lang GE. Diabetic macular edema. Ophthalmologica. 2012;227 Suppl 1:21-29.
-
(2012)
Ophthalmologica
, vol.227
, pp. 21-29
-
-
Lang, G.E.1
-
17
-
-
0012431804
-
Report of the expert committee on the diagnosis and classification of diabetes mellitus
-
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
-
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20.
-
(2003)
Diabetes Care
, vol.26
, pp. S5-20
-
-
-
18
-
-
0022347471
-
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group
-
No authors listed. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-1806.
-
(1985)
Arch Ophthalmol
, vol.103
, Issue.12
, pp. 1796-1806
-
-
-
19
-
-
84856404530
-
Role of inflammation in the pathogenesis of diabetic retinopathy
-
El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19(1):70-74.
-
(2012)
Middle East Afr J Ophthalmol
, vol.19
, Issue.1
, pp. 70-74
-
-
El-Asrar, A.M.1
-
20
-
-
84868208071
-
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results
-
Diabetic Retinopathy Clinical Research N
-
Diabetic Retinopathy Clinical Research N, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three-year randomized trial results. Ophthalmology. 2012;119(11):2312-2318.
-
(2012)
Ophthalmology
, vol.119
, Issue.11
, pp. 2312-2318
-
-
Elman, M.J.1
Qin, H.2
-
21
-
-
58149242792
-
Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema
-
Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053-1060.
-
(2008)
Retina
, vol.28
, Issue.8
, pp. 1053-1060
-
-
Kook, D.1
Wolf, A.2
Kreutzer, T.3
-
22
-
-
67650043196
-
Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial
-
Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina. 2009;29(3):292-299.
-
(2009)
Retina
, vol.29
, Issue.3
, pp. 292-299
-
-
Lam, D.S.1
Lai, T.Y.2
Lee, V.Y.3
-
23
-
-
77952253587
-
Correlation between visual acuity and foveal microstructural changes in diabetic macular edema
-
Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010;30(5):774-780.
-
(2010)
Retina
, vol.30
, Issue.5
, pp. 774-780
-
-
Otani, T.1
Yamaguchi, Y.2
Kishi, S.3
-
24
-
-
78649824641
-
Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema
-
Alasil T, Keane PA, Updike JF, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology. 2010;117(12):2379-2386.
-
(2010)
Ophthalmology
, vol.117
, Issue.12
, pp. 2379-2386
-
-
Alasil, T.1
Keane, P.A.2
Updike, J.F.3
-
25
-
-
21244445737
-
Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema
-
Bakri SJ, Shah A, Falk NS, Beer PM. Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema. Eye (Lond). 2005;19:686-688.
-
(2005)
Eye (Lond)
, vol.19
, pp. 686-688
-
-
Bakri, S.J.1
Shah, A.2
Falk, N.S.3
Beer, P.M.4
-
26
-
-
84863232320
-
An increase in intraocular pressure after intravitreal steroid injection facilitates reduction of macular edema
-
Chae JB, Joe SG, Yang SJ, Lee JY, Kim JG, Yoon YH. An increase in intraocular pressure after intravitreal steroid injection facilitates reduction of macular edema. Eye (Lond). 2012;26(3):479-480.
-
(2012)
Eye (Lond)
, vol.26
, Issue.3
, pp. 479-480
-
-
Chae, J.B.1
Joe, S.G.2
Yang, S.J.3
Lee, J.Y.4
Kim, J.G.5
Yoon, Y.H.6
-
27
-
-
79961231326
-
Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema
-
Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol. 2011;5:1011-1016.
-
(2011)
Clin Ophthalmol
, vol.5
, pp. 1011-1016
-
-
Marey, H.M.1
Ellakwa, A.F.2
-
28
-
-
84941313014
-
Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15
-
Aref AA, Scott IU, Oden NL, et al. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15. JAMA Ophthalmol. 2015;133(9):1022-1029.
-
(2015)
JAMA Ophthalmol
, vol.133
, Issue.9
, pp. 1022-1029
-
-
Aref, A.A.1
Scott, I.U.2
Oden, N.L.3
-
29
-
-
40949161371
-
A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection
-
Im L, Allingham RR, Singh I, Stinnett S, Fekrat S. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J Glaucoma. 2008;17(2):128-132.
-
(2008)
J Glaucoma
, vol.17
, Issue.2
, pp. 128-132
-
-
Im, L.1
Allingham, R.R.2
Singh, I.3
Stinnett, S.4
Fekrat, S.5
-
30
-
-
34247400587
-
Pharmacokinetics of intravitreal bevacizumab (Avastin)
-
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855-859.
-
(2007)
Ophthalmology
, vol.114
, Issue.5
, pp. 855-859
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
Pulido, J.S.4
Singh, R.J.5
-
31
-
-
11144253482
-
Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection
-
Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138(6):1046-1048.
-
(2004)
Am J Ophthalmol
, vol.138
, Issue.6
, pp. 1046-1048
-
-
Inoue, M.1
Takeda, K.2
Morita, K.3
Yamada, M.4
Tanigawara, Y.5
Oguchi, Y.6
-
32
-
-
48149111861
-
Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye
-
Kamppeter BA, Cej A, Jonas JB. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology. 2008;115(8):1372-1375.
-
(2008)
Ophthalmology
, vol.115
, Issue.8
, pp. 1372-1375
-
-
Kamppeter, B.A.1
Cej, A.2
Jonas, J.B.3
-
33
-
-
77952889192
-
A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2
-
Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078-1086.e2.
-
(2010)
Ophthalmology
, vol.117
, Issue.6
, pp. 1078-1078e2
-
-
Michaelides, M.1
Kaines, A.2
Hamilton, R.D.3
-
34
-
-
84975698767
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial
-
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359.
-
(2016)
Ophthalmology
, vol.123
, Issue.6
, pp. 1351-1359
-
-
Wells, J.A.1
Glassman, A.R.2
Ayala, A.R.3
|